Hikma Pharmaceuticals PLC · LSE:HIK
Hikma Pharmaceuticals — Investor Day (October 2012)
12 slides from Hikma Pharmaceuticals's investor day presentation, Oct 11, 2012
Slide 1: Hikma Pharmaceuticals — Global Injectables Analyst and Investor Day
Hikma Pharmaceuticals — Global Injectables Analyst and Investor Day 11 October 2012
Slide 2: Disclaimer
> Page 1 This document, which has been issued by Hikma Pharmaceuticals PLC (the “Company’), comprises the written materials/slides for a bresentetian, This document aid ts canténts are confidential and may not be reproduced, veuisnbuled or passed an, dieully ur indireaty, to any ‘other persor or pub
Slide 3: Quality
AIKMB Quality
Slide 4: Agenda for the day
Agenda for the day AIKMIN. 09:00-09.10 Welcome | Mike Raya 09.10-09.30 Global Injectables - Overview and strategic objectives Said Darwazah 09.30-10.00 Global Injectables — Delivering our strategy | Riad Mechlaoui 10.00-10.15 Coffee break 10.15-10.40 | US Injectables Mike Raya 10.40—11.05 European I
Slide 5: Quality
AIKMB Quality
Slide 6: Global Injectables — Overview and strategic objectives
Global Injectables — Overview and strategic objectives A. | | Group at a glance | | | Evolution of our global Injectables business | | | Our global Injectables business today | Our strategy for growth Pages
Slide 7: Group at a glance
Group at a glance AK INJECTABLES {tira atta moncactrr of ualty stele iectabies Selling specialised Us FDA approved manufacturing generic and branded cite mine Us, Berit sn injectable products S*""Y = globally ‘SedleIqul Dowtor Weptiioed and ‘ftetode products Broad pote incuding ‘CNS, antanfective,ea
Slide 8: Building our expertise in injectables since 1978
Building our expertise in injectables since 1978 Alvin Entered ints Greenfield injectable | |” Manutacturing ot Tay acquisition — Ribosepharin Hew yoplilisation licensing agreement | | facility coinpletedin | | injectable powdarad | | aclaing lvophiisation {Gaimany) fslty inaugurated with Fujisona P
Slide 9: An important driver of growth for the Group
An important driver of growth for the Group a Hikma Group and Injectables revenue, 2002 to 2011 CAGR, 2002 to 2011 - Organic: 29.3% CAGR, 2002 to 2011 inc. MSI - 36.5% 900 + a 800 700 | $ million 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 mRestof the Group slnjectables Source : Company inform
Slide 10: Differentiating our business through more specialised products
Differentiating our business through more specialised products AIKMA 2005 group revenue by segment H1 2012 group revenue by segment 1.8% 0.5% 10.5% 43.9% @ 48.7% 35.5% =Generics Branded minjectables. = Other We have signi ctables business Source : Hikma Annual Reports Pages
Slide 11: Leveraging our global footprint
Leveraging our global footprint A US ‘capaeiumies Focusing on growing our Vian mpses ‘ork share by value fon developing our MANUFACTURNIC: portato an source Innes ‘COMPETITORS Hoepra APP, Son ‘aren Regent agent Ccetssin enone 60.7% vsti of Gioup sales” “H12012. Group sales Page 10 EUROPE —_Yairsnpns
Slide 12: Our strategy for future growth in global Injectables
Our strategy for future growth in global Injectables > Building on our strong market presence in the US, Europe and MENA >» Leveraging our excellent quality track record > Developing our broad product portfolio and technical capabilities > Continuing our track record of bringing new products to mark